Scolaris Content Display Scolaris Content Display

Chemotherapy for resistant or recurrent gestational trophoblastic neoplasia

This is not the most recent version

References

Additional references

Alazzam 2009

Alazzam M, Tidy J, Hancock BW, Osborne R. First line chemotherapy in low risk gestational trophoblastic neoplasia. Cochrane Database of Systematic Reviews 2009, Issue 1. [DOI: 10.1002/14651858.CD007102.pub2]

Bagshawe 1976

Bagshawe KD. Risk and prognostic factors in trophoblastic neoplasia. Cancer 1976;38(3):1373‐85.

Chan 2009

Chan Lee, Harriet O Smith, Seung J Kim. Epidemiology. Gestational trophoblastic disease (3rd edn.), International Society for the Study of Trophoblastic Diseases. ISSTD, 2009:49‐96.

Covens 2006

Covens A, Fialici VL, Burger RA, Osborne R, Chen MD. Phase II trial of pulse dactinomycin as salvage therapy for failed low‐risk gestational trophoblastic neoplasia. Cancer 2006;107(6):1280‐6.

CTCAE 2009

Common Terminology Criteria for Adverse Events (CTCAE). http/ctep/cancer.gov.

DerSimonian 1986

DerSimonian R, Laird N. Meta‐analysis in clinical trials. Controlled Clinical Trials 1986;7:177‐88.

Dobson 2000

Dobson LS, Lorigan PC, Coleman RE, Hancock BW. Persistent gestational trophoblastic disease: results of MEA (methotrexate, etoposide and dactinomycin) as first‐line chemotherapy in high risk disease and EA (etoposide and dactinomycin) as second‐line therapy for low risk disease. British Journal of Cancer 2000;82:1547‐52.

El‐Helw 2005

El‐Helw LM, Seckl MJ, Haynes R, Evans LS, Lorigan PC, Long J, et al. High‐dose chemotherapy and peripheral blood stem cell support in refractory gestational trophoblastic neoplasia. British Journal of Cancer 2005;93:620‐1.

El‐Helw 2007

El‐Helw LM, Hancock BW. Treatment of metastatic gestational trophoblastic neoplasia. Lancet Oncology 2007;8(8):715‐24.

Fisher 2009

Fisher R. Genetics. In: BW Hancock, M Seckl, RS Berkowitz, LA Cole editor(s). Gestational trophoblastic disease (3rd edn.), International Society for the Study of Trophoblastic Diseases. ISSTD, 2009.

Hammond 1973

Hammond CB, Borchert LG, Tyrey L, Creaman WT, Parker RT. Treatment of metastatic trophoblastic disease: good and poor prognosis. American Journal of Obstetrics and Gynecology 1973;115(4):451‐7.

Hancock 2006

Hancock BW, Nazir K, Everard JE. Persistent gestational trophoblastic neoplasia after partial hydatidiform mole incidence and outcome. Journal of Reproductive Medicine 2006;51:764‐6.

Higgins 2003

Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta‐analyses. BMJ 2003;327:557‐60.

Higgins 2009

Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions 5.0.0 [updated September 2009]. The Cochrane Collaboration, 2008. Available from www.cochrane‐handbook.org.

Homeseley 1988

Homeseley HD, Blessing JA, Rettenmaier M, Capizzi RL, Major FJ, Twiggs LB. Weekly intramuscular methotrexate for nonmetastatic gestational trophoblastic disease. Obstetrics and Gynecology 1988;72(3):413‐8.

Khan 2003

Khan F, Everard J, Ahmed S, Coleman RE, Aitkin M, Hancock BW. Low‐risk persistent trophoblastic disease treated with low‐dose methotrexate: efficacy, acute and long term effects. British Journal of Cancer 2003;89(12):2197‐201.

Kohorn 2000

Kohorn EI, Goldstein DP, Hancock BW, Kim SJ, Lurain JR, Newlands E, et al. Combining the staging system of the International Federation of Gynecology and Obstetrics with the scoring system of the World Health Organization for trophoblastic neoplasia. Report of the Working Committeeo the International Society for the Study of Trophoblastic Disease and International Gynecologic Cancer Society. International Journal of Gynecological Cancer 2000;10:84‐8.

Lurain 2005

Lurain J, Nejad B. Secondary chemotherapy for high‐risk gestational trophoblastic neoplasia. Gynecologic Oncology 2005;97:618‐23.

Matsui 2005

Matsui H, Suzuka K, Yamazawa K, Tanaka N, Mitsuhashi A, Seki K, et al. Relapse rate of patients with low‐risk gestational trophoblastic tumor initially treated with single‐agent chemotherapy. Gynecologic Oncology 2005;96:616‐20.

McNeish 2002

McNeish IA, Strickland S, Holden L, Rustin GJ, Foskett M, Seckl MJ, et al. Low‐risk persistent gestational trophoblastic disease: outcome after initial treatment with low‐dose methotrexate and folinic acid from 1992 to 2000. Journal of Clinical Oncology 2002;20(7):1838‐44.

Nagan 2002

Nagan HY. The FIGO staging for gestational trophoblastic neoplasia 2000, FIGO Committee Report. International Journal of Gynecology and Obstetrics 2002;77:285‐7.

Newlands 2000

Newlands ES, Mulholland PJ, Holden L, Seckl MJ, Rustin GJ. Etoposide and cisplatin/etoposide, methotrexate, and actinomycin D (EMA) chemotherapy for patients with high‐risk gestational trophoblastic tumors refractory to EMA/cyclophosphamide and vincristine chemotherapy and patients presenting with metastatic placental site trophoblastic tumors. Journal of Clinical Oncology 2000;18:854‐9.

Palmer 1994

JR Palmer. Advances in the epidemiology of gestational trophoblastic disease. Journal of Reproductive Medicine 1994;39(3):155‐62.

Sebire 2002

Sebire NJ, Foskett M, Fisher RA, Rees H, Seckl M, Newlands E. Risk of partial and complete hydatidiform molar pregnancy in relation to maternal age. British Journal of Obstetrics and Gynaecology 2002;109:99‐102.

Seckl 2009

Seckl MJ. Presentation and management of persistent gestational trophoblastic disease (GTD) and gestational trophoblastic tumours (GTT) in the United Kingdom. In: BW Hancock, M Seckl, RS Berkowitz, LA Cole editor(s). Gestational trophoblastic disease (3rd edn.), International Society for the Study of Trophoblastic Diseases. ISSTD, 2009.

Tham 2003

Tham BW, Everard JE, Tidy JA, Drew D, Hancock BW. Gestational trophoblastic disease in the Asian population of Northern England and North Wales. British Journal of Obstetrics and Gynaecology 2003;110(6):555‐9.

Wang 2008

Wang J, Short D, Sebire NJ, Lindsay I, Newlands ES, Schmid P, et al. Salvage chemotherapy of relapsed or high‐risk gestational trophoblastic neoplasia (GTN) with paclitaxel/cisplatin alternating with paclitaxel/etoposide (TP/TE). Annals of Oncology 2008;19:1578‐3.

WHO GTD 1983

WHO. Gestatational trophoblastic diseases. WHO Technical report Sens 6921983.